首页> 外国专利> Protofibril binding antibodies and their use in diagnostic therapeutic methods for Parkinson's disease, dementia with Lewy bodies and other alpha-synucleinopathies

Protofibril binding antibodies and their use in diagnostic therapeutic methods for Parkinson's disease, dementia with Lewy bodies and other alpha-synucleinopathies

机译:原纤维结合抗体及其在帕金森氏病,路易体痴呆和其他α-突触核蛋白病的诊断治疗方法中的用途

摘要

An antibody or a fragment thereof that binds to the human α-synuclein protofibrils having a molecular weight in a range of between 1,000 and 5,000 kDa, in which the binding of the antibody or fragment to each of the monomers of α-synuclein and β-synuclein monomers is at least 100 times less than the binding of the antibody or fragment to the protofibrils of human α-synuclein, the antibody or fragment having three variable heavy sequences (VH) of CDR (VH-CDR-1, VH-CDR-2 and VH-CDR-3) and three variable light sequences (VL) of CDR (VL-CDR-1, VL-CDR-2 and VL-CDR-3) and wherein the antibody or fragment thereof has a combination of CDR sequences selected from the following combinations: (a) VH-CDR-1: SEQ ID NO: 22, VH-CDR-2: SEQ ID NO: 28, VH-CDR-3: SEQ ID NO: 35, VL-CDR-1: SEQ ID NO: 41, VL-CDR-2: SEQ ID NO: 47 and VL-CDR-3: SEQ ID NO: 50, (b ) VH-CDR-1: SEQ ID NO: 23, VH-CDR-2: SEQ ID NO: 29, VH-CDR-3: SEQ ID NO: 36, VL-CDR-1: SEQ ID NO: 42, VL-CDR-2: SEQ ID NO: 47 and VL-CDR-3: SEQ ID NO: 50, (c) VH-CDR-1: SEQ ID NO : 24, VH-CDR-2: SEQ ID NO: 30, VH-CDR-3: SEQ ID NO: 37, VL-CDR-1: SEQ ID NO: 43, VL-CDR-2: SEQ ID NO: 48 and VL-CDR-3: SEQ ID NO: 51, (d) VH-CDR-1: SEQ ID NO: 25, VH-CDR-2: SEQ ID NO: 31, VH-CDR-3: SEQ ID NO: 38, VL-CDR-1: SEQ ID NO: 44, VL-CDR-2: SEQ ID NO: 47 and VL-CDR-3: SEQ ID NO: 52, (e) VH-CDR-1: SEQ ID NO : 26, VH-CDR-2: SEQ ID NO: 32, VH-CDR-3: SEQ ID NO: 39, VL-CDR-1: SEQ ID NO: 45, VL-CDR-2: SEQ ID NO: 47 and VL-CDR-3: SEQ ID NO: 53, (f) VH-CDR-1: SEQ ID NO: 23, VH-CDR-2: SEQ ID NO: 33, VH-CDR-3: SEQ ID NO: 37, VL-CDR-1: SEQ ID NO: 43, VL-CDR-2: SEQ ID NO: 48 and VL-CDR-3: SEQ ID NO: 54, and (g) VH-CDR-1: SEQ ID NO: 27, VH-CDR-2: SEQ ID NO: 34, VH-CDR-3: SEQ ID NO: 40, VL-CDR-1: SEQ ID NO: 46, VL-CDR-2: SEQ ID NO: 49 and VL-CDR-3: SEQ ID NO: 55.
机译:结合至分子量在1,000至5,000kDa之间的人α-突触核蛋白原纤维的抗体或其片段,其中所述抗体或片段与α-突触核蛋白和β-的每个单体的结合突触核蛋白单体至少比抗体或片段与人α-突触核蛋白原纤维的结合少100倍,该抗体或片段具有CDR的三个可变重序列(VH)(VH-CDR-1,VH-CDR- 2和VH-CDR-3)和CDR的三个可变轻序列(VL)(VL-CDR-1,VL-CDR-2和VL-CDR-3),其中抗体或其片段具有CDR序列的组合选自以下组合:(a)VH-CDR-1:SEQ ID NO:22,VH-CDR-2:SEQ ID NO:28,VH-CDR-3:SEQ ID NO:35,VL-CDR-1 :SEQ ID NO:41,VL-CDR-2:SEQ ID NO:47和VL-CDR-3:SEQ ID NO:50,(b)VH-CDR-1:SEQ ID NO:23,VH-CDR- 2:SEQ ID NO:29,VH-CDR-3:SEQ ID NO:36,VL-CDR-1:SEQ ID NO:42,VL-CDR-2:SEQ ID NO:47和VL-CDR-3:序列号:50,(c)VH-CDR-1:SEQ ID NO:24,VH-CDR-2:SEQ ID NO:30,VH-CDR-3:SEQ ID NO:37,VL-CDR-1:SEQ ID NO:43,VL-CDR-2:SEQ ID NO:48和VL-CDR-3:SEQ ID NO:51,(d)VH-CDR-1:SEQ ID NO:25,VH-CDR-2:SEQ ID NO:31,VH-CDR-3:SEQ ID NO:38,VL-CDR-1:SEQ ID NO:44,VL-CDR-2:SEQ ID NO:47和VL-CDR-3:SEQ ID NO: :52,(e)VH-CDR-1:SEQ ID NO:26,VH-CDR-2:SEQ ID NO:32,VH-CDR-3:SEQ ID NO:39,VL-CDR-1:SEQ ID NO:45,VL-CDR-2:SEQ ID NO:47和VL-CDR-3:SEQ ID NO:53,(f)VH-CDR-1:SEQ ID NO:23,VH-CDR-2:SEQ ID NO:33,VH-CDR-3:SEQ ID NO:37,VL-CDR-1:SEQ ID NO:43,VL-CDR-2:SEQ ID NO:48和VL-CDR-3:SEQ ID NO: :54,和(g)VH-CDR-1:SEQ ID NO:27,VH-CDR-2:SEQ ID NO:34,VH-CDR-3:SEQ ID NO:40,VL-CDR-1:SEQ ID NO:46,VL-CDR-2:SEQ ID NO:49和VL-CDR-3:SEQ ID NO:55。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号